Targets › CDK8
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Aug 2027.
Component of the Mediator complex, a coactivator involved in regulated gene transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. (UniProt, P49336)
Open in Phaseline: the race on CDK8, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ryvu Therapeutics | RVU120 CDK8 and CDK19 inhibitor | CDK8, CDK19 | Phase 2 | Acute Myeloid Leukemia | Aug 2027 |
Acute Myeloid Leukemia (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.